Kolexia
Daste Amaury Oncologie médicale
Daste Amaury
Oncologie médicale
Hôpital Saint-André
Bordeaux, France
239 Activités
677 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome épidermoïde Carcinome épidermoïde de la tête et du cou Tumeurs de la tête et du cou Néphrocarcinome Tumeurs du rein Métastase tumorale Tumeurs du poumon Récidive tumorale locale

Collaborateurs

Voir plus
Ravaud Alain
Ravaud Alain
Hôpital Saint-André, Bordeaux, France
Gross-Goupil Marine
Gross-Goupil Marine
Hôpital Saint-André, Bordeaux, France
Even Caroline
Even Caroline
Gustave-Roussy, Villejuif, France
Domblides Charlotte
Domblides Charlotte
Hôpital Saint-André, Bordeaux, France

Industries

Voir plus
Merck-Serono
20 collaboration(s)
Dernière en 2023
BMS
19 collaboration(s)
Dernière en 2023
MSD
13 collaboration(s)
Dernière en 2023
OLIMPE
2 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
iintune-1: An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Essai Clinique (Takeda Pharmaceutical)   07 mars 2024
AdCC_2023-01: A Phase Ib Study of OBT076 or OBT076 Followed by Balstilimab in Patients With Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (AdCC) of the Head and Neck (H&N)
Essai Clinique (Groupe d'Oncologie Radiothérapie Tête Et Cou)   06 mars 2024
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION): A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Essai Clinique (Emd Serono)   05 mars 2024
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors: Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
Essai Clinique (Merus N.V.)   01 mars 2024
Immunotherapy for head and neck squamous cell carcinoma: current status and perspectives.
Immunotherapy   21 décembre 2023
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors: Phase 1/2 Open-label Study of BMS-986466 in Combination With Adagrasib With or Without Cetuximab in Participants With KRAS G12C-mutant Advanced Solid Tumors
Essai Clinique (BMS)   08 décembre 2023
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors: A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors
Essai Clinique (Calico Life Sciences LLC)   05 décembre 2023
186P Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: An EORTC IMMUcan sub-project
Abstract Book of the ESMO Immuno-Oncology Congress 2023 6-8 December 2023   01 décembre 2023
Retraitement par inhibiteurs de points de contrôles immunitaires chez des patients ayant présenté une arthrite inflammatoire immunomédiée : étude observationnelle multicentrique
36e Congrès Français de Rhumatologie   01 décembre 2023
Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.
RMD open   29 novembre 2023